Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study - Clinical Therapeutics
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial - The Lancet Neurology
Frontiers | Clinical Features Observed in General Practice Associated With the Subsequent Diagnosis of Progressive Supranuclear Palsy | Neurology
NCT03419403
1.0 Abstract
Dr. Bower receives research funding from Abbvie Pharmaceuticals for a clinical trial on PSP Mr. T is a 66 year old man,
PDF) Impact of the Adalimumab Patient Support Program on Clinical Outcomes in Ankylosing Spondylitis: Results from the COMPANION Study
AbbVie hoping for early data readout for anti-tau Alzheimer's drug | Fierce Biotech
1. Abstract
Anti-Tau Drugs for PSP Move into Phase II - CurePSP
1.0 Abstract
The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares - ACR Meeting Abstracts
PDF) Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis
Sony officially announces PSP Go
Participation in an innovative patient support program reduces prescri | PPA
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab – Author's reply
PRECLINICAL AND CLINICAL DEVELOPMENT OF ABBV-8E12, A HUMANIZED ANTI-TAU ANTIBODY, FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES • The Journal of Prevention of Alzheimer's Disease
All Crohn's disease patient selection results. Abbreviations: CD,... | Download Scientific Diagram
AbbVie to present new and updated data from 22 abstracts
AbbVie Ends Tau Antibody Study - CurePSP
Clinical Study Protocol M15-563 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Incorporating Administra
Is Patient Support Program (PSP) Participation Associated with Longer Persistence and Greater Adherence Among New Users of Adalimumab? - ACR Meeting Abstracts
1.0 Abstract
Summary of Clinical Trial Results
navocaftor (GLPG3067) - Larvol Sigma
